Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Preferred Shares: 2011-2016

Historic Preferred Shares for Arrowhead Pharmaceuticals (ARWR) over the last 4 years, with Sep 2016 value amounting to $16.

  • Arrowhead Pharmaceuticals' Preferred Shares changed negligibly% to $16 in Q3 2016 from the same period last year, while for Sep 2016 it was $16, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $16 for FY2016, which is negligibly% changed negligibly from last year.
  • Arrowhead Pharmaceuticals' Preferred Shares amounted to $16 in Q3 2016, which was down 0.00% from $16 recorded in Q2 2016.
  • Arrowhead Pharmaceuticals' 5-year Preferred Shares high stood at $51 for Q4 2013, and its period low was $10 during Q2 2013.
  • For the 3-year period, Arrowhead Pharmaceuticals' Preferred Shares averaged around $17.27, with its median value being $16 (2016).
  • Data for Arrowhead Pharmaceuticals' Preferred Shares shows a peak YoY increase of 110.00% (in 2014) and a maximum YoY decrease of 64.71% (in 2014) over the last 5 years.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Preferred Shares (Quarterly) stood at $51 in 2013, then plummeted by 64.71% to $18 in 2014, then dropped by 11.11% to $16 in 2015, then remained steady at $16 in 2016.
  • Its Preferred Shares stands at $16 for Q3 2016, versus $16 for Q2 2016 and $16 for Q1 2016.